Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Liraglutide in Type 2 Diabetes
NCT05268237Phase 2Recruiting
- Sponsor
- BioLingus
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of liraglutide in type 2 diabetes mellitus (T2DM), sponsored by BioLingus. Started Apr 2023; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05268237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05268237.